Eurostars project is awarded to VitroScan
VitroScan has been awarded project funding for personalized ovarian cancer therapy selection - 3D SELECT
VitroScan closes €800k seed funding round
Press release - VitroScan closes funding round to deliver proof-of-concept for treatment response prediction
EIT Health Belgium-Netherlands awards VitroScan with HeadStart Funding
HeadStart Funding supports start-ups in taking their next step to the market by accelerating market entry and by creating new economic activity more effectively.
Best Poster Prize ESMO 2017
VitroScan presented first results on ovarian cancer at the ESMO congress: Predicting PARPi sensitivity in patient derived ex vivo 3D tumour cultures. The poster was awarded with best poster prize.
Exclusive license to OcellO's Drug Response Platform
VitroScan acquires an exclusive license to develop to OcellO's technology to develop predictive diagnostics.